These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The use of protease inhibitors. A sampling of opinions. Interview by Deborah J Cotton.
    Author: Corey L, Hirsch M, Skowron G, Vella S.
    Journal: AIDS Clin Care; 1996 May; 8(5):37-41. PubMed ID: 11363605.
    Abstract:
    In a roundtable discussion with AIDS Clinical Care, four leading HIV clinical investigators--Drs. Martin Hirsch, Stefano Vella, Lawrence Corey, and Gail Skowron--discuss their views on the state-of-the-art antiviral therapy for HIV infection: protease inhibitors. Martin Hirsch, the director of clinical AIDS research at Massachusetts General Hospital, recommends a combination of a protease inhibitor and one or two reverse transcriptase inhibitors for patients in the advanced stages of AIDS. Lawrence Corey, head of the Program in Infectious Diseases at the Fred Hutchison Cancer Center, states that protease inhibitors should not be taken alone due to the risk of developing resistance, but that they should be used with a nucleoside analog. Meanwhile, Gail Skowron, an infectious disease consultant for Roger Williams Hospital, recommends using a protease inhibitor alone if a patient is not able to tolerate other antiretrovirals, noting that more information is needed on combining protease inhibitors. A clinical trial is needed to determine if protease inhibitors should be used early or late in infection. Hirsch suggests using nucleoside combinations first and then resorting to protease inhibitors if needed. Skowron recommends treating high viral loads aggressively with combination therapy, including a protease inhibitor.
    [Abstract] [Full Text] [Related] [New Search]